Antibody-dependent enhancement of virus infection is a process whereby virus-antibody complexes initiate infection of cells via Fc receptor-mediated endocytosis. We sought to investigate antibody-dependent enhancement of feline infectious peritonitis virus infection of primary feline peritoneal macrophages in vitro. Enhancement of infection was assessed, after indirect immunofluorescent-antibody labelling of infected cells, by determining the ratio between the number of cells infected in the presence and absence of virus-specific antibody. Infection enhancement was initially demonstrated by using heat-inactivated, virus-specific feline antiserum. Functional compatibility between murine immunoglobulin molecules and feline Fc receptors was demonstrated by using murine anti-sheep erythrocyte serum and an antibody-coated sheep erythrocyte phagocytosis assay. Thirty-seven murine monoclonal antibodies specific for the nucleocapsid, membrane, or spike proteins of feline infectious peritonitis virus or transmissible gastroenteritis virus were assayed for their ability to enhance the infectivity of feline infectious peritonitis virus. Infection enhancement was mediated by a subset of spike protein-specific monoclonal antibodies. A distinct correlation was seen between the ability of a monoclonal antibody to cause virus neutralization in a routine cell culture neutralization assay and its ability to mediate infection enhancement of macrophages. Infection enhancement was shown to be Fc receptor mediated by blockade of antibody-Fc receptor interaction using staphylococcal protein A. Our results are consistent with the hypothesis that antibody-dependent enhancement of feline infectious peritonitis virus infectivity is mediated by antibody directed against specific sites on the spike protein.
Antibody-dependent enhancement of virus infection is a process whereby virus-antibody complexes initiate infection of cells via Fc receptor-mediated endocytosis. We sought to investigate antibody-dependent enhancement of feline infectious peritonitis virus infection of primary feline peritoneal macrophages in vitro. Enhancement of infection was assessed, after indirect immunofluorescent-antibody labelling of infected cells, by determining the ratio between the number of cells infected in the presence and absence of virus-specific antibody. Infection enhancement was initially demonstrated by using heat-inactivated, virus-specific feline antiserum. Functional compatibility between murine immunoglobulin molecules and feline Fc receptors was demonstrated by using murine anti-sheep erythrocyte serum and an antibody-coated sheep erythrocyte phagocytosis assay. Thirty-seven murine monoclonal antibodies specific for the nucleocapsid, membrane, or spike proteins of feline infectious peritonitis virus or transmissible gastroenteritis virus were assayed for their ability to enhance the infectivity of feline infectious peritonitis virus. Infection enhancement was mediated by a subset of spike protein-specific monoclonal antibodies. A distinct correlation was seen between the ability of a monoclonal antibody to cause virus neutralization in a routine cell culture neutralization assay and its ability to mediate infection enhancement of macrophages. Infection enhancement was shown to be Fc receptor mediated by blockade of antibody-Fc receptor interaction using staphylococcal protein A. Our results are consistent with the hypothesis that antibody-dependent enhancement of feline infectious peritonitis virus infectivity is mediated by antibody directed against specific sites on the spike protein.
Feline infectious peritonitis virus (FIPV) is a member of the family Coronaviridae. Coronaviruses are plus-sense, single-stranded RNA viruses with three major structural proteins, the spike (S), membrane (M), and nucleocapsid (N) proteins (18) . FIPV infects domestic as well as exotic cats and produces an ultimately fatal disease called feline infectious peritonitis (FIP) (2, 30, 39) . One of the most perplexing aspects of the pathogenesis of FIP is the frequent occurrence of accelerated, more fulminant disease upon FIPV challenge of seropositive as compared with seronegative cats. Accelerated FIP was first documented when Pedersen and Boyle showed that the onset of clinical disease among experimentally infected kittens correlated with the appearance of serum antibodies (31) . Weiss and Scott confirmed these results, demonstrating that the onset of viremia, clinical signs, thrombocytopenia, lymphopenia, and the appearance of viral antigen and necrotizing lesions in affected tissues all occurred earlier in seropositive kittens than in seronegative kittens (48, 49) . Survival times were also significantly shorter for seropositive kittens (31, 48) . In addition, seronegative kittens given immune serum (31, 47) or anti-FIPV immunoglobulin G (IgG) (31) before challenge developed clinical disease in the same manner and over the same time course as did seropositive kittens. The demonstration of immune complex deposition in FIP by Jacobse-Geels et al. (13, 14) initially seemed to explain both the pathologic changes of FIP and the phenomenon of accelerated FIP. However, a Ab-coated SRBC phagocytosis assay. An Fc receptor-mediated phagocytosis assay was conducted as previously described (42) . Fresh SRBC were pelleted and washed three times and then resuspended to 5% (vol/vol) in PBS. Equal volumes of this 5% SRBC solution and either rabbit anti-SRBC serum (1:128) (Organon Teknika, Durham, N.C.), murine anti-SRBC serum (1:128) (see above), or PBS were incubated at 37°C for 30 min. The erythrocyte-Ab complexes were then pelleted and washed three times in PBS and resuspended to 1% (vol/vol) in L-15 medium. Macrophages in eight-chamber Lab-Tek slides were inoculated with the 1% SRBC solutions (0.1 ml per chamber) and incubated for 60 min at 37°C. The slides were then rinsed in PBS, dipped in distilled water, and stained with May-Grunwald-Giemsa stain.
In vitro assay for enhancement of FIPV infectivity. The assay for enhancement of virus infectivity was adapted from the method described by Stoddart (41) . Macrophages were infected with virus 22 to 24 h after having been seeded onto Lab-Tek slides. Each MAb (as ascites fluid) or antiserum sample was initially evaluated at a dilution (in CMM) of 1:64 and serial twofold dilutions from 1:512 to 1:16,384. FIPV UCD1 stock virus was diluted to 2 x 106 TCID5Jml in CMM. Equal volumes of diluted virus plus Ab (or plus CMM for the wells to be infected by virus alone) were mixed and incubated at 37°C for 30 min. Macrophage cultures in triplicate wells were then washed once with PBS and inoculated with 400 ,ul of preincubated virus plus Ab or virus plus medium. Inoculation with CMM alone and mixtures of MAb or antiserum plus medium served as negative controls. To rule out enhancement of virus infection by nonspecific serum factors, heat-inactivated preimmune feline serum as well as coronavirus-negative murine serum was incubated with FIPV as described above, and the level of infection achieved was compared with that obtained with virus alone.
Following inoculation, macrophages were cultured for 60 min at 37°C, after which the Lab-Tek chambers were thoroughly washed with PBS to remove nonadsorbed virus and replenished with 300 ,ul of CMM. At 1146, using serial twofold dilutions from 1:32 to 1:1,048,576. Because of the limited number of primary macrophages available from a single peritoneal lavage procedure, evaluation of the two strains of virus was usually conducted by using macrophages collected on different days. Inoculation of virus plus enhancing FIPV-specific feline antiserum served as a positive control for enhancement and as a control for day-to-day variation in the macrophages in all assays.
Indirect IFA labelling. Indirect IFA labelling of infected macrophages or CrFKC was conducted as previously de- scribed (42), with slight modification. Briefly, slides were incubated with a 1:2,000 dilution (in PBS) of FIPV-specific, hyperimmune feline antiserum in a humidified chamber for 60 min at room temperature. The slides were then thoroughly washed with 0.1% BSA in PBS and gently blotted dry. Slides were subsequently incubated with a 1:50 dilution (in PBS) of fluorescein isothiocyanate-conjugated goat antifeline IgG (Organon Teknika) for 30 min at 37°C, washed with 0.1% BSA, and counterstained with 0.002% Evans blue stain.
Quantitation of infection enhancement. Following indirect IFA labelling, each slide was evaluated for the number of infected (IFA-positive) cells per well. The degree of FIPV infection enhancement caused by each dilution of antiserum or MAb (enhancement factor [EF]) was calculated as follows: the mean number of infected cells per well for the wells infected in the presence of a given dilution of Ab was divided by the mean number of infected cells per well for the wells infected with virus alone (41) .
Staphylococcal protein A blockade of the Fc portion of enhancing Abs. Parallel enhancement assays were conducted in the presence or absence of soluble staphylococcal protein A (P 6650; Sigma) as previously described (41) . Protein A was added to preincubated virus-Ab mixtures (1:512 dilution of antiserum, 1:1,024 dilution of ascites fluid) to a final concentration of 200 ,ug/ml. Virus-Ab mixtures were made in media without fetal bovine serum to avoid competition for protein A binding. The protein A-containing mixtures were incubated for an additional 60 min at 37°C before inoculation of macrophages.
Construction of RPV-S. A recombinant raccoonpox virus expressing the S protein of FIPV 79-1146 (RPV-S) was constructed (25) essentially as described by Mackett et al. (19, 20) . Briefly, a full-length clone of the S gene of FIPV 79-1146, kindly supplied by M. C. Horzinek (Utrecht, The Netherlands) as a BamHI fragment in pGS20 (46) , was inserted into the tk gene of raccoonpox virus. Recombinant viruses were selected by plaque titration in TK-143B cell monolayers under overlay medium containing 30 ,ug of bromodeoxyuridine (Boehringer Mannheim, Indianapolis, Ind.) per ml. Presence of the FIPV S gene in the recombinant virus was determined by dot blot hybridization (21) . S protein expression was determined by immunoblotting (29) , RIPA (40) , and indirect IFA labelling.
CrFKC were grown to confluence on eight-chamber LabTek slides and infected with RPV-S at a multiplicity of infection of 3. Twenty-four hours after infection (at the time of optimal plaque formation), the slides were processed for indirect IFA labelling using each of the MAbs assayed for enhancement. (Fig. 1) . The peak level of enhancement of strain UCD1 occurred at a serum dilution of 1:2,048. At this dilution of antiserum, there was a 56-fold increase in the number of macrophages infected compared with macrophages infected with virus alone. The peak EF for strain 79-1146 was 34 and occurred at a serum dilution of 1:8,192 . Each data point represents the mean EF calculated from triplicate wells. (The remainder of the enhancement data [ Fig. 4 through 10] is presented in similar graphic form, although the scales on the axes vary to accommodate the data.) Infection was not detected among macrophages inoculated with medium alone or with antiserum plus medium. In addition, no effect on the level of infection was noted in the presence of preimmune (coronavirus antibody-negative) serum.
RESULTS
To reduce the inherent variability involved in using primary macrophages, all of the data contained in Fig. 1 (Fig. 4 through 10) . As in Fig. 1 , all of the data contained in Fig. 4 
DISCUSSION
Although the immunologic aspects of FIP in vivo have been well documented since 1980 (13, 49) , ADE of FIPV infection of macrophages in vitro has been investigated only recently (41) . The experiments reported here were designed to address this in vitro phenomenon more completely and to begin to define the specific viral components responsible for the induction of enhancing ABs.
ADE of virus infectivity in other virus systems has been quantified by using several different methods, including determination of the number of cells infected by IFA labelling (44) or infectious center assays (37) or by titration of the amount of virus (38) , antigen (44) , or reverse transcriptase activity (10) generated. We chose to evaluate the number of macrophages infected during a single cycle of infection. In doing so, we are evaluating primarily the enhancing effect of Ab at the level of virus uptake and initiation of infection. In contrast, if levels of total virus output from populations of cells infected in the presence or absence of Ab are compared, the effect of Ab both at the cell surface and throughout virus replication must be considered. Previous reports of ADE of virus infectivity have not provided a consensus as to whether measurement of the number of cells infected and the titer of virus produced lead to the same assessment of enhancement (12, 36) . We began by examining the ability of FIPV-specific feline antiserum to mediate ADE of infection. Our experiments, using the same assay but different virus stocks, different antisera, and different macrophage donor cats, confirm previous results (41) and demonstrate that ADE of FIPV infectivity is a real and reproducible phenomenon. The results of our study of MAb-dependent enhancement of FIPV infectivity clearly confirm the hypothesis that enhancement is mediated by Abs to specific sites on the S protein of FIPV. These data also provide the first in vitro correlate to the results of a previous in vivo study in which vaccination of cats with a recombinant vaccinia virus expressing the S protein of FIPV 79-1146 caused ADE of disease (45) . MAbs have previously been used to define the viral proteins responsible for inducing enhancing Abs in other virus systems (17, 24, 35) . While it is generally assumed that ADE of virus infectivity is mediated by Ab to surface proteins, it was important to test MAbs not only to the S and M proteins but also to the N protein of FIPV, since enhancement of dengue virus infectivity has been demonstrated with a MAb specific for a nonenvelope protein (9) .
The overall bell-shaped distribution of enhancement factor relative to dilution of antiserum or ascites fluid is consistent with the results of other studies of ADE (6, 23, 26, 41) . Our results also show that in some instances, low dilutions/high concentrations of Ab can actually reduce the level of infection to below that obtained with virus alone, resulting in an EF of <1. This pattern is most easily seen in Fig. 4 (MAb 18H9.1) but was also evident with polyclonal feline antiserum ( Fig. 1) and with MAbs 3G7, 17E1.6, 18A7.4, and 23F4.5 ( Fig. 5 through 8, respectively) . This phenomenon at low dilutions of Ab has also been documented in prior studies of ADE of virus infectivity (6, 23, 41, 44) . FIPV is typical of other virus systems in that Ab-mediated virus uptake and infection occur via an Fc receptor-mediated endocytosis pathway which can be blocked by lysomotrophic amines (41) . During endocytosis, there are both uptake and fusion phases of the internalization process. The bell-shaped enhancement profiles may reflect a need to optimize virion and Ab molecule concentrations for complex formation before uptake can occur. At high concentrations of Ab, the virions may be so coated With Ab that they are unable to approach and fuse with the endosome membrane due to steric hindrance (7, 8, 27) (Fig. 9 ) and 23F8.1 (Fig. 10) Fig. 4 through 7, respectively) , while two MAbs enhanced 79-1146 more than UCD1 (MAbs 23F4.5 and 23F8.1; Fig. 8 and 10 , respectively). It is therefore likely that the strain variation in enhancement seen here is related to the specific epitopes recognized by the enhanc- Perhaps the most paradoxical of our results is the strong correlati'on between a MAb's ability to mediate both neutralization and ADE of FIPV infectivity. It is important to e.mphasize that the neutralization ability of the MAbs in this study'was defined in a standard virus neutralization assay using CrFKC and not a's the prozonelike effect that occurred at high conc'entrations of Ab in the macrophage assay system. As such, it is likely that the ability of Ab to mediate both neutralization and enhancement is dependent on the specific epit'ope involved and not simply the con'centration of Ab. Previous investigations of ADE have also shown that a given Ab can both neutralize and enhance virus infectivity. The most exhaustive data come from work done with dengue virus (8, 23 for virus fusion to the endosomal membrane. FIPV is unlike many of the other coronaviruses because its S protein is not cleaved during synthesis in routine cell culture (1, 18) . However, a trypsin-sensitive cleavage site has been biochemically identified for FIPV 79-1146 and FECV 1683 (1), 
